Introduction
============

The discovery that some hormones elevate the second messenger cyclic AMP (cAMP) without triggering canonical effects such as increased phosphorylase activity ([@B44]; [@B36]) indicated that cAMP may be compartmentalized in cells ([@B22]). Studies of cAMP compartmentalization rely upon methods to sense and manipulate signaling enzyme activities in space and time ([@B88]). The first sensor of intracellular cAMP ('FlCRhR') was constructed by fluorescein-labeling PKA catalytic subunits and rhodamine-labeling the regulatory subunits of the tetrameric kinase ([@B1]). Release of the catalytic subunits upon binding of cAMP to the regulatory subunits can be detected as a reduction in Forster resonance energy transfer (FRET; [@B1]). The FlCRhR probe was revolutionary as it enabled the first visualizations of cAMP compartmentalization ([@B4]; [@B37]). However, the sensor must be microinjected since its fluorescent labels are not genetically encoded. This technical hurdle has limited the influence of the FlCRhR probe.

The subsequent development of genetically encoded sensors of cAMP ([@B112]) and PKA activity ([@B116]), in tandem with methods for manipulating both the enzyme that synthesizes cAMP -- adenylyl cyclase (AC) -- and molecular interactions that support cAMP signaling, has initiated a new wave of discoveries concerning cAMP signaling ([@B22]). Studies with these novel tools have helped to establish the necessity for targeting PKA to its substrates by anchoring to A-kinase anchoring proteins (AKAPs; [@B81]; [@B116]; [@B14]). The tools have been applied to reveal a small nuclear population of anchored PKA ([@B84]). Furthermore, they have illuminated how PKA interacts spatiotemporally with phosphodiesterase (PDE) enzymes that degrade cAMP ([@B109]), with the exchange-protein activated by cyclic AMP (Epac; [@B17]), and with Ca^2+^ signals ([@B11]). This genetically encoded tool set has also been applied to establish a role for localized cAMP signaling in diseases ([@B29]) such as heart failure ([@B68]), muscular dystrophy ([@B80]), diabetes ([@B115]), breast cancer ([@B34]), and adrenal Cushing's syndrome ([@B6]).

In this review, we introduce genetically encoded sensors of cAMP and PKA activity, before discussing tools based upon ACs. We describe sequences that are available for targeting such tool proteins to specific sub-cellular locations and for modifying protein interactions involving cAMP signaling proteins. Importantly, further functionality can arise when the different classes of tools are combined, and we highlight studies that exploit this kind of synergy. Finally, we consider how the tool set might be extended and combined in novel ways to enable further advances in the understanding of cAMP signaling.

Genetically Encoded Sensors for Monitoring cAMP Dynamics
========================================================

There are three types of cAMP receptors in higher organisms: PKAs, Epacs, and cyclic-nucleotide-gated channels (CNGCs). Genetically encoded sensors are available that derive from each class of endogenous cAMP receptor ([@B105]). Sensors derived from PKAs and Epacs rely upon fusions to variants of green fluorescent protein (GFP) that undergo decreased FRET upon elevation of cAMP. Sensors derived from CNGCs can also employ measurements using patch clamp electrophysiology to detect changes in conductance upon binding of cAMP to the channel. The first genetically encoded FRET-based cAMP sensor was constructed by fusing an improved GFP to the C-terminus of the PKA catalytic subunit and a blue GFP variant (EBFP) to the C-terminus of type-II regulatory (RII) PKA subunits ([@B112]). Respective substitution of EBFP and GFP with cyan and yellow fluorescent proteins yielded an improved sensor that is less prone to photobleaching ([@B113]). This allowed real time imaging of cAMP fluctuations in cardiomyocytes in response to the β-adrenergic agonist norepinephrine or the broad spectrum PDE inhibitor isobutyl-methyl-xanthine (IBMX), and helped to establish that type IV PDEs are the critical PDE class for degrading cAMP following activation with norepinephrine in cardiomyocytes ([@B59]).

The discovery of Epac1 and Epac2 ([@B13]; [@B43]) opened the door for development of unimolecular cAMP sensors based upon these cAMP-dependent GTPase activators ([@B15]; [@B66]; [@B72]). Unimolecular sensors based on Epacs exhibit higher FRET efficiency (increase in FRET signal from maximal to minimal cAMP) of ∼20--30% compared to ∼8% for multimolecular PKA-based sensors. Epac probes also show better temporal resolution ([@B66]), and there are no concerns regarding balancing expression of the donor and acceptor fluorophores in unimolecular probes. For these reasons, Epac probes are now the most popular option for sensing cAMP fluctuations. The latest optimized Epac-based probes include pH-insensitive Ci/Ce Epac2-camps ([@B24]) (**Figure [1A](#F1){ref-type="fig"}**) and the Epac1-based probes ICUE3 ([@B16]) and ^T^Epac^VV^ ([@B48]; [@B53]) although the original probes exhibit good FRET efficiency and are still popular. CNGC-based cAMP sensors excel in temporal resolution of cAMP fluctuations ([@B75]; [@B25]). The first example of this approach exploited rat CNG2 expression in human embryonic kidney-293 (HEK-293) cells ([@B75]). Measurement of Ca^2+^ flux through the channels as a proxy for cAMP elevation using electrophysiology supported the existence of cellular cAMP microdomains. Mutations can be incorporated into the CNG2 to tailor it for sensing cAMP: C460W improves cAMP sensitivity, E583M improves cAMP specificity over cGMP, and removal of residues 61-90 abrogates channel regulation by Ca^2+^/calmodulin ([@B76]) (**Figure [1B](#F1){ref-type="fig"}**). A C460W/E583M double CNG2 mutant was used as a sensor to reveal that both G protein coupled receptor kinases (GRKs) and PKA stimulate PDE degradation of cAMP following β2-AR simulation of HEK-293 cells ([@B110]). A common way to apply CNG2 is to combine expression of the channel with the Ca^2+^ dye Fura-2, allowing measurement of Ca^2+^ influx by imaging rather than electrophysiology ([@B25]; [@B76], [@B77]; [@B79]). For example, the E583M CNG2 variant was applied in this way to establish the necessity of PKA anchoring for negative feedback through PKA activation of type IV PDEs ([@B109]). CNGCs can also be adapted as FRET sensors ([@B67]). The hyperpolarization-activated CNG2 (HCN2) has a higher sensitivity than CNG2, and exhibits as wide a dynamic range as a cAMP FRET sensor when YFP and CFP are fused either side of a single HCN2 cAMP binding domain ([@B67]).

![**Tools for monitoring cyclic AMP (cAMP) signaling.** Two cAMP sensors and an A-kinase activity reporter are illustrated. **(A)** Cartoon showing mechanism for cAMP sensing by 'Ci/C-Epac2-camps,' which is based on the second cAMP binding domain of Epac2. Elevation of cAMP leads to separation of citrine and cerulean fluorescent proteins that can be detected as a decrease in FRET **(B)** cAMP sensor based on cyclic nucleotide-gated channel 2 (CNG2), which is modified with removal of residues 61--90 to prevent Ca^2+^/calmodulin regulation, and the substitutions C460W/E583M for high affinity and specificity for cAMP. Elevation of cAMP leads to increased flux of Ca^2+^ which can be detected using Ca^2+^ dyes or by measuring current across the membrane. **(C)** AKAR4 contains a central FHA1 domain. PKA phosphorylation of threonine within the motif 'LRRATLVD' leads to association of phosphothreonine with FHA1, which can be detected as an increase in FRET between the terminal fluorescent proteins.](fphar-06-00164-g001){#F1}

Genetically encoded cAMP probes have been applied to investigate different facets of cAMP signaling. For example, they have helped build upon initial observations of cAMP oscillations in [@B7] and [@B32]. Epac-based probes demonstrate that cAMP oscillations can be evoked in cell lines including MIN6 cells ([@B50]) and HEK293 cells ([@B104]). cAMP oscillations have also been monitored in β-cells using evanescent-wave-microscopy in combination with fluorescently labeled RII-CAAX and C subunits ([@B20]). This approach shows that Ca^2+^ amplifies but is not essential for glucose-induced cAMP oscillations in β-cells ([@B20]). Ca^2+^ typically oscillates in tandem with cAMP, and a related area of focus has been the basis of interplay between cAMP and Ca^2+^ signals at the level of signaling proteins. Epac probes reveal that distinct pools of cAMP center on specific isoforms of AC ([@B99]), with the Ca^2+^-activated cyclase AC8 occupying a prominent role in linking Ca^2+^ signals to localized cAMP elevation ([@B107]; [@B3]).

A key advantage of genetically encoding sensors is that transgenic animals expressing the sensors can be generated. Imaging of cAMP fluctuations has been achieved in pancreatic islets ([@B46]) using genetically engineered mice that selectively express a PKA-based cAMP sensor in pancreatic islets. This approach was exploited to show that that glucose triggers cAMP elevation independent of Ca^2+^ ([@B46]). Another study monitored cAMP changes upon activation of either β1 or β2 adrenergic receptors within small sarcolemmal areas by employing adrenergic receptor knockout mice transgenically expressing Epac2-camps ([@B68]). This study revealed that β2 adrenergic receptors are restricted to deep transverse tubules ([@B68]). Development of transgenic fruit flies expressing cAMP sensors ([@B55]) has also proved to be useful. In particular, *Drosophila* expressing Epac1-camps with an upstream activating sequence for GAL4 ([@B89]) have enabled detailed investigation of how neuropeptides including pigment dispersing factor modulate cAMP in neurons during circadian rhythms ([@B19]; [@B71]; [@B98]; [@B111]). In sum, an impressive array of sensors and delivery options are now available for monitoring intracellular cAMP fluctuations.

Fluorescence-Based Sensors for Monitoring PKA Activity
======================================================

One potential limitation of cAMP sensors is that they may not reflect cAMP receptor activation if the receptors and active cyclase are not co-localized. For PKA, genetically encoded A-kinase activity reporters (AKARs) may be utilized to monitor kinase activity more directly ([@B57]). The first AKAR was constructed by placing YFP and CFP either side of a PKA consensus phosphorylation sequence derived from Kemptide and the phospho-serine/threonine-binding protein 14-3-3τ ([@B116]). Phosphorylation at the PKA consensus sequence causes association of the central elements that may be detected as a concomitant increase in FRET ([@B116]). A second-generation sensor, AKAR2, incorporates a Forkhead-associated (FHA) domain in tandem with a lower affinity PKA recognition site. This modification improves the reversibility of the reporter ([@B115]). This reporter was first applied to investigate interaction of insulin and isoproterenol stimulation of adipocytes. Using AKAR2, the authors found that chronic insulin treatment delayed PKA activation following addition of low concentrations of the β-AR agonist isoproterenol ([@B115]). Conversely, PKA response to stimulation with either forskolin or caged cAMP was not affected by prior chronic insulin treatment. This suggested that insulin reduces PKA localization to a pool of cAMP associated with β-ARs. This notion was corroborated by anti-β-AR immunoprecipitation experiments that revealed decreased interaction of PKA RII subunits with β-ARs following dual treatment with insulin and isoproterenol ([@B115]). This detail might have been missed if a cAMP sensor had been employed rather than AKAR2. Systematic improvement of AKAR reporters is ongoing ([@B56]; [@B69]). The latest reporter, AKAR4, features the fluorescent protein variants Cerulean and cpVenus ([@B12]) (**Figure [1C](#F1){ref-type="fig"}**).

A-kinase activity reporters have also been widely applied. For example, they have been used to validate stapled PKA anchoring disruptor peptides ([@B101]), and to confirm that Leu206Arg substitution in Cα subunits (associated with Adrenal Cushing's Syndrome) leads to constitutive kinase activation ([@B6]). They are often utilized in parallel with cAMP sensors, for example, in imaging fluctuations of cAMP and PKA activity induced by neural activity in retinal cells ([@B18]); to investigate cAMP/PKA dynamics at the centrosome ([@B96]); and in the study of neurite outgrowth including a forskolin-coated glass bead contact procedure for cultured hippocampal neurons ([@B90]). As with genetically encoded cAMP sensors, it is possible to express AKARs in transgenic animals. For example, PKA activity dynamics have been imaged in *Drosophila* expressing AKAR2 ([@B27]). In this study, [@B42] performed crosses with learning and memory deficient mutant fly lines to establish that the AC Rutabaga acts as a coincidence detector during aversive and appetitive learning ([@B27]). AKAR-expressing mice have also been developed, and exploited to image real-time PKA activity in mouse epidermis and small intestine ([@B42]). These whole-organism studies underline the benefits of genetically encoding reporters in comparison to techniques that rely upon microinjection ([@B1]).

Tools for Manipulating Adenylyl Cyclase Activity
================================================

The ability to control cAMP elevations with spatiotemporal precision can help to reveal how cAMP signaling is organized in time and space ([@B88]). In analogous fashion to the discovery of light-activated channelrhodopsins for artificially depolarizing cells ([@B62]), photo-active adenylyl cyclases (PACs) have been identified in photo-sensitive microbes ([@B39]; [@B83]; [@B94]). Advantages of genetically encoded PACs over cAMP uncaging approaches ([@B72]; [@B86]) include the ability to deliver into whole animals, and the option to localize the PAC within cells by fusion to subcellular targeting sequences. The first PAC to be characterized and utilized was discovered in *Euglena.* This unicellular flagellate relies on a PAC in photophobic behavior ([@B39]). *Euglena* PAC comprises two subunits, PACα and PACβ. Each subunit consists of two blue light receptor using flavin adenine nucleotide (BLUF) domains paired with two AC domains. Activation of the BLUF domains with blue light leads to a conformational change that activates the AC domains. Both PAC subunits respond to blue light with a maximal increase in AC activity of ∼80-fold. The PACα subunit is more active than PACβ in both light and dark conditions ([@B39]), so applications of *Euglena* PAC have utilized the α subunit ([@B8]; [@B5]; [@B103]).

Smaller PACs have subsequently been discovered in species other than *Euglena*, including *Beggiatoa* PAC (bPAC; [@B83]; [@B94]) (**Figure [2A](#F2){ref-type="fig"}**). bPAC comprises 350 residues, which facilitates transgenic delivery in comparison to PACα (1019 residues). bPAC also exhibits better responsiveness to blue light than PACα, and cyclase activity decreases faster for bPAC upon return to the dark ([@B83]; [@B94]). A different class of PAC has been identified in *Microcoleus* (mPAC) that relies on a blue light-responsive light oxygen voltage domain coupled to an AC domain ([@B74]). mPAC compares favorably to bPAC when expressed *in vivo*, although its responsiveness to blue light is worse *in vitro*, suggesting that a cellular co-factor may support its proper function ([@B74]). Both bPAC and mPAC require lower light intensity for cyclase activation than PACα ([@B83]; [@B94]; [@B74]), so are better suited for application in tissue samples where light penetration is a challenge. A noteworthy alternative to PACs is to employ a C-terminally truncated version of soluble AC (sAC~t~) that can be activated by addition of bicarbonate ([@B84]) (**Figure [2B](#F2){ref-type="fig"}**). This approach is compatible with simultaneous monitoring of cAMP concentration and PKA activity with FRET-based probes ([@B84]; see Combinatorial Applications).

![**Tools for triggering cAMP elevation. (A)** Illustration of *Beggiatoa* PAC (bPAC) demonstrating how light illumination of the BLUF domain is coupled to activation of AC activity. **(B)** A truncated version of soluble AC (sAC~t~) responds to elevated bicarbonate by catalyzing cAMP synthesis.](fphar-06-00164-g002){#F2}

The utility of PACs is demonstrated by studies up to the level of whole animals. PACα has been expressed in cholinergic neurons ([@B103]), motor neurons ([@B8]), and olfactory receptor neurons (ORNs; [@B5]) in *Drosophila*. This has enabled conceptual progress including the establishment of a specific class of ORNs that mediate olfactory avoidance behavior ([@B5]). PACα has been applied to demonstrate a key role for cAMP in growth cone turning in *Xenopus* ([@B65]). [@B65] found that local pulses of blue light on distal parts of growth cones expressing PACα were sufficient to maintain orientation of axon outgrowth toward the midline despite blockade of a key Netrin-1 receptor. The potential utility of bPAC has been demonstrated in *Aplysia* ([@B61]), *Toxoplasma* ([@B35]), and in *Xenopus*, HEK293 cells and *Drosophila* ([@B87]). [@B40] have shown how bPAC can be used to control sperm motility and maturation. Furthermore, specific expression of bPAC in *Drosophila* renal tubule in combination with pharmacological manipulations has revealed the distinct roles fulfilled by PKA and Epac in controlling secretion from principal and stellate cells ([@B23]). The field is poised for further insights as application of PACs becomes more widespread.

Sequences for Subcellular Targeting and Modifying Protein--Protein Interactions
===============================================================================

An important characteristic of genetically encoding sensors and manipulators of cAMP signaling is that they can be combined with targeting sequences to direct them to specific subcellular compartments. This approach facilitates investigation of spatial aspects of cAMP signaling. In addition, a number of sequences are available for manipulating interaction between PKA and its anchoring sites. A straightforward way to control the location of a given genetically encoded tool is to fuse it with a full-length signaling protein of interest. This option has been taken with proteins including AC8 ([@B106], [@B108]; [@B24]), full-length PKA RII ([@B116]), different PDEs ([@B38]), SOD2 ([@B114]), phospholamban ([@B92]), and Hsp20 ([@B91]). In cases where a good structural understanding is available, fusions are possible to shorter protein domains, such as with the dimerization and docking (D/D) domain of PKA regulatory subunits for tethering at anchoring sites ([@B14]), or with the PDE4D-association region from mAKAP ([@B17]).

The structural interface between PKA and AKAPs is well understood: all AKAPs present a ∼20 amino acid amphipathic helix that binds within a shallow hydrophobic groove on the D/D domain of PKA regulatory subunits ([@B30]; [@B47]; [@B85]). Native and synthetic AKAP anchoring helix sequences are available for modifying PKA anchoring or targeting genetically encoded tools including cAMP sensors (summarized in **Table [1](#T1){ref-type="table"}**). A popular sequence is Ht31 ([@B81]), which is the native anchoring helix of AKAP-Lbc. Using a combination of structural information and peptide array screening, synthetic sequences have been developed with altered binding preferences for RI and RII PKA regulatory subunits. These include the RII-selective sequences AKAP-*is* ([@B2]), Super-AKAP-*is* ([@B30]), and AKB-II ([@B9]); and the RI-selective sequences RIAD ([@B10]; [@B97]) and AKB-RI ([@B9]). Studies that utilize sequences for modifying protein--protein interactions typically apply them exogenously as peptides, such as stearated Ht31 ([@B31]), and delivery approaches in this vein are still improving ([@B101], [@B102]). Some studies have taken advantage of their genetic encodability. For example, sequences including AKAP-*is* ([@B17]) and AKB-RI/RII ([@B9]) have been expressed using transfection, and Ht31 has been incorporated in a transgenic mouse ([@B70]).

###### 

Sequences for modifying interactions between cyclic AMP (cAMP) signaling proteins and subcellular targeting.

  Purpose                                                     Name and specifications                                                                                                                              Reference
  ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------
  **Sequences for modifying protein--protein interactions**                                                                                                                                                        
  Binding to the D/D domain of PKA RII subunits               Ht31 (AADLIEEAASRIVDAVIEQVKA). *K*~D~ = 2.2 nM for RIIα; 1.3 μM for RIα                                                                              [@B81], [@B2]
                                                              AKAP-*is* (QIEYLAKQIVDNAIQQA). *K*~D~ = 0.4 nM for RIIα, 277 nM for RIα                                                                              [@B2], [@B17]
                                                              Super-AKAP-*is* (QIEYVAKQIVDYAIHQA). On filter assay binds RIIα 4× more and RIα 12.5× less efficiently than AKAP-*is*                                [@B30]
                                                              AKB-RII (VQGNTDEAQEELLWKIAKMIVSDVMQQ). *K*~D~ = 2.7 nM for RIIα, 2.5 μM for RIα                                                                      [@B9]
  Binding to the D/D domain of PKA RI subunits                RIAD (LEQYANQLADQIIKEATE). *K*~D~ = 1 nM for RIα, 1800 nM for RIIα                                                                                   [@B10], [@B97]
                                                              AKB-RI (FEELAWKIAKMIWSDVFQQ). *K*~D~ = 5.2 nM for RIα; 450 nM for RIIα                                                                               [@B9]
  Localizing with type I PKA                                  RIα (1--64)                                                                                                                                          [@B14]
  Binding to AKAP anchoring helices                           RIIβ (amino acids 1--49)                                                                                                                             [@B14]
  Specifically binding to the AKAP18 anchoring helix          RSelectAKAP18 (PKA RIIα 1--45 with I3V, I5L, T10D, Q14G substitutions)                                                                               [@B28]
  Binding to PDE4D                                            mAKAP (1286--1831)                                                                                                                                   [@B17]
  **Sequences for subcellular targeting**                                                                                                                                                                          
  Plasma membrane                                             C-terminal addition of polybasic-CAAX sequence, e.g., GKKKKKKSKTKCVIM. CAAX box undergoes farnesylation                                              [@B15], [@B21], [@B86], [@B12]
  Plasma membrane (cholesterol-rich)                          N-terminal addition of Lyn kinase sequence, e.g., MGCIKSKRKDNLNDD, that undergoes myristoylation and palmitoylation                                  [@B95], [@B12], [@B84]
  Nuclear localization                                        C-terminal addition of nuclear localization signal PKKKRKVEDA                                                                                        [@B15], [@B95], [@B84]
  Nuclear export                                              C-terminal addition of nuclear export sequence LPPLERLTL                                                                                             [@B84]
  Sarcoplasmic reticulum                                      C-terminal addition of the helical transmembrane region (PQQARQKLQNLFINFCLILICLLLICIIVMLL) of phospholamban                                          [@B56]
  Outer mitochondrial membrane                                N-terminal addition of the targeting peptide yTom70                                                                                                  [@B51]
                                                              N-terminal addition of MitoDAKAP1 (MAIQLRSLFPLALPGMLALLGWWWFFSRKK), a mitochondrial signal sequence derived from D-AKAP1                             [@B9], [@B15], [@B54], [@B12]
  Mitochondrial matrix                                        N-terminal addition of the mitochondrial matrix targeting signal encoded in the first 12 amino acids of subunit IV of human cytochrome oxidase *c*   [@B15], [@B51]

An additional recent innovation is the development of variants of PKA regulatory subunits with selective anchoring properties ([@B28]). A structure-based bacteriophage screening procedure ([@B100]) enabled identification of variants of the RII D/D domain with substitutions that enable selective anchoring to AKAP18 and AKAP2 ([@B28]). RSelect subunits can potentially be applied to drive PKA either specifically to or away from individual AKAPs ([@B28]). In most tissues, with rare exceptions ([@B31]), multiple AKAPs are present and an important challenge is to identify the PKA substrates associated with different AKAP--PKA signaling complexes ([@B29]). It is possible to genetically abrogate specific PKA anchoring sites, for example, in the case of AKAP150 ΔPKA knock-in mice in which the PKA anchoring helix in AKAP150 is absent ([@B60]). Therefore, a potentially more novel application of RSelect subunits is to combine them with anchoring disruptors such as Ht31. This approach enables PKA catalytic subunits to be driven to a single AKAP within the cell ([@B28]).

A variety of sequences may be utilized for targeting to organelles (**Table [1](#T1){ref-type="table"}**). Inclusion of C-terminal polybasic-CAAX sequences enables targeting to the plasma membrane ([@B15]; [@B21]; [@B86]; [@B12]), whereas N-terminal addition of a sequence derived from Lyn kinase targets specifically to cholesterol-rich regions of plasma membrane ([@B95]; [@B12]; [@B84]). C-terminal addition of the sequence 'PKKKRKVEDA' enables nuclear localization ([@B15]; [@B95]; [@B84]), whereas addition of 'LPPLERLTL' at the same terminus drives nuclear export ([@B84]). Targeting to the sarcoplasmic reticulum is possible by fusing with the helical transmembrane domain of phospholamban ([@B56]). Furthermore, sequences are available for targeting to both the outer mitochondrial membrane (OMM; [@B9]; [@B15]; [@B54]; [@B12]; [@B51]), and to the mitochondrial matrix ([@B15]; [@B51]). At the whole animal level, systems are also available for driving cell-type specific expression of genetically encoded tools. These include the UAS/GAL4 system in *Drosophila* ([@B89]), and the reverse tetracycline transactivator (rtTA)/doxycycline system in transgenic mice ([@B46]). Overall, there is an impressive arsenal of sequences at the experimenter's disposal for manipulating the location and binding properties of cAMP signaling proteins and genetically encoded tools.

Combinatorial Applications
==========================

The tools described in this review have been combined in different ways to make conceptual breakthroughs that would not have been possible if the tools were applied in isolation. The majority of combinations consist of fusions to either sequences derived from cAMP signaling proteins or to subcellular targeting sequences. We will also consider two exceptional studies that have utilized highly innovative combinations of the tool set ([@B64]; [@B84]).

The first study involving AKAR1 set a precedent for combining a cAMP sensor with sequences derived from cAMP signaling proteins. Fusion of AKAR1 to the PKA RII subunit revealed that PKA phosphorylation occurs more quickly if PKA is tethered in proximity to its substrate ([@B116]). This finding underlined the importance of anchoring PKA to its substrates. A similar approach has been to fuse an Epac-based cAMP sensor to AC8 ([@B106], [@B108]), for example, to demonstrate that this Ca^2+^-sensitive AC responds to Ca^2+^ entering through L-type Ca^2+^ channels ([@B24]). Fusions to isolated domains of cAMP signaling proteins have also been insightful. Fusing Epac-based sensors to the D/D domains of different PKA regulatory subunit classes ([@B14]; [@B80]) has helped to establish that PDE4 associates with RII subunits, whereas PDE2 acts in the vicinity of RI subunits ([@B14]). By applying this approach in cardiomyocytes, [@B14] also revealed that the β-AR agonist isoproterenol triggers relatively higher cAMP accumulation with RII subunits, whereas hormones including glucagon induce raised cAMP in the vicinity of the RI subunit. This mechanism allows G protein-coupled receptor specific patterns of cAMP signaling to occur within the same cell. A fusion of the PDE-binding region of mAKAP (residues 1286--1831) with the AKAR2 reporter has also been applied to demonstrate that dominant active MEK5 prolongs PKA activity after cAMP elevation with forskolin ([@B17]).

Targeting FRET-based sensors using subcellular targeting sequences has also proved to be valuable. Fusions of AKAR reporters with membrane-targeting sequences ([@B86]; [@B12]) have revealed, for example, that basal PKA activity is higher in cholesterol-rich 'raft' regions of membrane ([@B12]). Similarly, plasma membrane-targeting of an Epac-based cAMP sensor has helped to establish how a pre-assembled protein complex including RXFP1, AKAP79, AC2, β-arrestin 2, and PDE4D3 enables responses to sub-picomolar circulating concentrations of relaxin peptide ([@B33]). Comparison of PKA activity using AKAR4 targeted to either the mitochondrial matrix or OMM shows that PKA phosphorylation is more enduring at the OMM than in the cytosol due to diminished phosphatase activity at the OMM ([@B51]). A related approach has been to fuse a sequence that targets to the outer mitochondrial membrane to the PKA regulatory subunit-specific anchoring disruptors AKB-R1 and AKB-R2 ([@B54]). [@B54] expressed these fused sequences to prevent access of either type I or type II PKA to the plasma membrane. This approach revealed that leading-edge phosphorylation of PKA substrates requires type I PKA, with re-localization of type I PKA to the mitochondria inhibiting both the directional persistence and speed of cell migration ([@B54]).

Two highly innovative combinatorial approaches have been exploited to examine cAMP dynamics in recent years ([@B95]; [@B84]). [@B84] developed a novel technique called spatiotemporal manipulation of cAMP using sAC~t~ ([@B84]). They targeted sAC~t~ by fusing the bicarbonate-activated AC to sequences that target to either the plasma membrane, cytosol, or the nucleus ([@B84]). By monitoring cAMP accumulation or PKA activity with cytosolic or membrane-tethered sensors, the authors revealed that cAMP and PKA activity can be localized at either the plasma membrane or in the nucleus. Modeling the responses of cAMP and PKA to forskolin and nuclear sAC indicated that a pool of PKA resides in the nucleus. This prediction was subsequently confirmed by immunohistochemistry and immunoblotting ([@B84]). Another elegant innovation has been to red-shift FRET-based sensors of cAMP and PKA activity to enable simultaneous application with other fluorescent sensors. Red-shifted sensors typically include red fluorescent protein (RFP) variants such that FRET emission occurs at longer wavelengths than with typical fluorescent probes ([@B64]). This approach was taken to study a cAMP-Ca^2+^-PKA oscillatory circuit in MIN6 cells ([@B64]). [@B64] performed imaging of Fura-2 with either red-shifted AKAR or a red-shifted Epac-based cAMP sensor. Remarkably, the authors also utilized a novel dual detector that enables simultaneous PKA activity and cAMP detection (ICUEPID). Application of these tools showed that oscillations in MIN6 cells can be triggered by cAMP alone, and the authors speculate that such oscillations may provide a way for local PKA activity to be maintained for long periods of time ([@B64]). These two studies from the Zhang laboratory exemplify the potential benefits of combining different categories of tools in novel ways.

Considerations for Experimental Design
======================================

When deciding whether to employ one of the tools outlined in this review, one considers how the strengths, limitations, and challenges associated with the tool match up with the aims of an experiment. If spatial aspects of cAMP signaling are the emphasis of investigation, then the Epac-based cAMP probes ([@B48]; [@B53]) are a good option as they consist of relatively short sequences that can be directed to subcellular locations with targeting sequences (**Table [1](#T1){ref-type="table"}**). On the other hand, if a maxim is placed on temporal resolution, the CNG2 system may be the better option ([@B75]; [@B25]). Similarly, PACs such as bPAC ([@B83]; [@B94]) allow faster activation and de-activation than the bicarbonate-activated sAC~t~ ([@B84]). For tandem applications, the bicarbonate-activated sAC~t~ cyclase has the advantage that there is no concern about unwanted photoactivation when combined with FRET-based cAMP/PKA sensors ([@B84]). Similarly, red-shifted sensors can allow cAMP and PKA activity sensors to be applied simultaneously ([@B64]). The choice of tools will also be dictated by the availability of specialist equipment. For example, application of FRET-based sensors typically relies on a confocal microscope with appropriate lasers. If such a microscope is unavailable then recordings may be performed using a plate reader ([@B78]) although studies will be limited to the population level following this approach.

It is important to consider the potential off-target effects and distortions that may be caused by the tools. For example, if PKA is the focus of investigation, it is wise to avoid PKA-based cAMP sensors that may distort signaling by interacting with native PKA subunits. Any unwanted cellular changes resulting from long-term expression of genetically encoded tools can be limited by using inducible expression systems such as the tetracycline system ([@B58]). Another consideration is that cAMP sensors act as buffers for cAMP, potentially altering the amplitude and duration of cAMP transients in a similar way to alteration of free Ca^2+^ transients by dyes such as Fura-2 ([@B63]). Buffering effects can be at least ameliorated by taking care to express cAMP sensors at levels no higher than is necessary for reliable detection. Finally, one should also bear in mind that targeting and disruptor sequences may not always behave as desired. The specificity of disruptor sequences can be tested by performing negative control experiments with sequences such as Ht31-P in which the disruptor helix is destabilized by incorporation of a central proline ([@B109]). It is also good practice to image cells to check that localization sequences have partitioned within the cell as anticipated ([@B54]). Overall, the wide range of available tools means that a good technical solution is at hand for most experimental aims.

Conclusions and Prospects
=========================

The genetically encoded tool set for investigating cAMP signaling has expanded rapidly over the last 15 years. There are now a multitude of options for monitoring intracellular fluctuations in cAMP, with Epac-based probes emerging as the most popular sensor class ([@B16]; [@B48]). AKAR reporters enable PKA activity to be monitored more directly, while experimenters can artificially elevate cAMP levels by photoactivating PACs or stimulating sAC with bicarbonate. The functionality of these tools can be enhanced by combining with an impressive array of sequences for modifying protein--protein interactions and subcellular targeting (**Table [1](#T1){ref-type="table"}**).

There is scope for improving the tools described in this review, developing novel tools, and combining the tools in new ways. Biosensors typically improve over time by incorporating modifications based on user feedback ([@B69]). This process may have reached the point of diminishing returns for FRET-based sensors and peptides derived from AKAP anchoring helices, whereas there is more potential for improvement of the more recently developed PACs and RSelect subunits. For example, an AC with a synthetic domain architecture has been shown to be activated by near-infrared light ([@B82]). This PAC is likely to be particularly advantageous for studies that require deep tissue penetration ([@B82]). It is worth noting that methods for calibrating FRET-based cAMP reporters are still improving ([@B49]). Genetically encoded sensors that incorporate Renilla luciferase for Bioluminescence resonance energy transfer (BRET) imaging ([@B73]; [@B41]) exhibit higher maximal signal-to-noise ratios than FRET-based sensors. Application of BRET sensors in live cell imaging could become more popular if light detectors can improve to overcome the relatively low light output of BRET compared to FRET. Although sequences for disrupting or selectively binding to either side of the AKAP--PKA interface are advanced (**Table [1](#T1){ref-type="table"}**), no equivalent sequences exist for interactions mediated by ACs, PDEs, or Epacs. If the structural and molecular basis of interactions involving these protein classes can be determined more precisely, it should be relatively straightforward to develop improved sequences using established peptide array screening ([@B2]; [@B9]) and directed evolution ([@B100]) approaches.

There are currently no existing technologies for activating PKA or Epac activity with temporal precision. One future avenue is to genetically encode unnatural amino acids such as caged lysine using the amber codon TAG ([@B26]; [@B45]) as a basis for enzyme activation upon illumination in a similar way to PACs. Future studies may also exploit an approach for light-gating protein-protein interactions that can be genetically encoded using sequences from a phytochrome signaling network ([@B52]). Further combinatorial possibilities that have been underexploited include fusions of PACs and sAC~t~ with the sequences listed in **Table [1](#T1){ref-type="table"}**. Many targeting studies have focused on the relation of cAMP signaling with different sub-structural features of cardiomyocytes ([@B14]; [@B68]). It will be valuable to perform analogous experiments to probe cAMP signaling in different neuronal compartments. Finally, the ICUEPID sensor ([@B64]) sets a precedent for how red-shifting FRET-based sensors can enable their combination with other technologies that rely upon illumination.

It is important to question the value of determining how cAMP signaling processes proceed with high spatial and temporal detail. The conceptual breakthrough that supported the development of the first β-blocker propranolol ([@B93]) indicates how current research targeted at spatiotemporal cAMP signaling might be useful in the long term. James Black was inspired to target β-ARs by experiments conducted by Raymond Ahlquist. Ahlquist established that there are two major classes of adrenergic receptor, with β-ARs underpinning responses to norepinephrine in the heart ([@B93]). An analogous classification of cAMP signaling processes at the sub-cellular level can provide a framework for selectively intervening in cAMP signaling with more precision than drugs that act at the level of the receptor. Combinatorial application of the genetically encoded tools described in this review is central to achieving the level of spatiotemporal detail necessary to open a path to a next generation of drugs that manipulate cAMP signaling.
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